{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:56:06Z","timestamp":1781337366133,"version":"3.54.1"},"reference-count":38,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["MDM Policy &amp; Practice"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    <jats:bold>Introduction.<\/jats:bold>\n                    Cost-effectiveness analyses are vital in guiding decisions on treatment reimbursement. Natural history models are central to these, enabling the estimation of long-term costs and quality-adjusted life-years (QALYs) in the absence of lifetime trial data. Rare disease data are often scarce, resulting in disease progression being estimated through clinical assumptions. This study aims to evaluate how different modeling approaches influence cost-effectiveness estimates in rare disease health technology assessments (HTAs), using Duchenne muscular dystrophy (DMD) as a case study.\n                    <jats:bold>Methods.<\/jats:bold>\n                    A published economic model was used to compare 2 approaches for estimating disease progression: an assumption-based method relying on clinical plausibility and data-driven methods using data from 1,005 patients with DMD across 8 studies. Transition probabilities were estimated assuming increasing flexibility of study heterogeneity and compared with a simulated treatment cohort. Models were evaluated by comparing incremental cost-effectiveness ratios (ICERs) across approaches. No gold standard exists, so the plausibility of predictions was evaluated by comparing survival and disease progression estimates to published milestones.\n                    <jats:bold>Results.<\/jats:bold>\n                    Results showed that although the assumption-based model was clinically plausible, it predicted higher QALY gains (0.77) and lower ICERs (\u00a31.96M per QALY) than data-driven methods did, which estimated QALY gains of 0.25, 0.26, 0.27, and 0.28 and ICERs of \u00a36.2M, \u00a36.2M, \u00a35.8M, and \u00a35.7M per QALY for the least to most flexible models, respectively.\n                    <jats:bold>Limitations.<\/jats:bold>\n                    No covariate effects or updated cost and utility data were incorporated, as the study purpose was a methodological comparison between approaches. Analyses were deterministic not probabilistic.\n                    <jats:bold>Conclusions and Implications.<\/jats:bold>\n                    This study emphasizes the critical role of model selection for HTA in rare diseases, showing that cost-effectiveness estimates from robust data-driven approaches can differ from clinically plausible assumption-based models.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>The choice of a natural history modeling method can drastically alter the cost-effectiveness results in rare disease evaluations.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>A case study in Duchenne muscular dystrophy demonstrates how different modeling approaches yield divergent cost-effectiveness outcomes.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Assumption-based models, even when clinically plausible, may underestimate measures of cost-effectiveness and result in less reliable guidance for decision makers.<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>Data-driven models using real-world patient data provide more reliable estimates for health technology assessment (HTA).<\/jats:p>\n                      <\/jats:list-item>\n                      <jats:list-item>\n                        <jats:p>This study offers practical guidance for analysts and HTA bodies on selecting robust modeling approaches in rare disease contexts.<\/jats:p>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:sec>","DOI":"10.1177\/23814683261447231","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:04:16Z","timestamp":1781175856000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Impact of Different Natural History Modeling Methods on Cost-Effectiveness Decisions: A Case Study in Duchenne Muscular Dystrophy"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-2150","authenticated-orcid":false,"given":"Jonathan","family":"Broomfield","sequence":"first","affiliation":[{"name":"Biostatistics Research Group, Department of Population Health Sciences, University of Leicester, Leicester, UK"},{"name":"Department of Respiratory Sciences, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Statistics &amp; Warwick Medical School, University of Warwick, Coventry, UK"},{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-8259","authenticated-orcid":false,"given":"Michael J.","family":"Crowther","sequence":"additional","affiliation":[{"name":"Red Door Analytics, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[{"name":"John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R","family":"Latimer","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Rutherford","sequence":"additional","affiliation":[{"name":"Biostatistics Research Group, Department of Population Health Sciences, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2008.10.003"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60872-7"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"issue":"7","key":"e_1_3_3_5_2","article-title":"Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold","volume":"31","author":"Griffiths EA","year":"2015","unstructured":"Griffiths EA, Hendrich JK, Stoddart SD, Walsh SC. Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold. Clinicoecon Outcomes Res. 2015;31(7):463\u201376.","journal-title":"Clinicoecon Outcomes Res"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01845-x"},{"key":"e_1_3_3_7_2","unstructured":"NICE. Interim process and methods of the highly specialised technologies programme updated to reflect 2017 changes. Available from: https:\/\/www.nice.org.uk\/media\/default\/about\/what-we-do\/nice-guidance\/nice-highly-specialised-technologies-guidance\/hst-interim-methods-process-guide-may-17.pdf. [Updated 2017; accessed 1 February 2025]."},{"key":"e_1_3_3_8_2","unstructured":"Zhang K Garau M. International cost-effectiveness thresholds and modifiers for HTA decision making. 2020. Available from: https:\/\/www.ohe.org\/publications\/international-cost-effectiveness-thresholds-and-modifiers-hta-decision-making\/. [Accessed 8 January 2025]."},{"key":"e_1_3_3_9_2","unstructured":"Perez-Kempner L Chowdhury E Lubojemska O. Unpacking NICE\u2019s review of the HST routing criteria: implications for manufacturers. 2024. Available from: https:\/\/www.parexel.com\/insights\/blog\/unpacking-nices-review-of-the-hst-routing-criteria-implications-for-manufacturers. [Accessed 14 January 2025]."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l7012"},{"key":"e_1_3_3_11_2","unstructured":"National Health Service (NHS). Muscular dystrophy. 2021. Available from: https:\/\/www.nhs.uk\/conditions\/muscular-dystrophy\/. [Accessed 14 January 2025]."},{"key":"e_1_3_3_12_2","unstructured":"NICE. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (NICE guideline). Available from: https:\/\/www.nice.org.uk\/guidance\/hst3. [Updated 2016; Accessed 28 January 2025]."},{"key":"e_1_3_3_13_2","unstructured":"NICE. Routine funding recommended for Duchenne muscular dystrophy gene therapy ataluren. Available from: https:\/\/www.nice.org.uk\/news\/articles\/routine-funding-recommended-for-Duchenne-muscular-dystrophy-gene-therapy-ataluren. [Updated 2022; accessed 14 January 2025]."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9949"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-016-0461-5"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","unstructured":"Landfeldt E Mayhew A Eagle M et al. Development and psychometric analysis of the Duchenne muscular dystrophy functional ability self-assessment tool (DMDSAT). Neuromuscul Disord. 2015;25(12):937\u201344. Available from: https:\/\/www.clinicalkey.es\/playcontent\/1-s2.0-S0960896615007397; DOI:10.1016\/j.nmd.2015.09.012","DOI":"10.1016\/j.nmd.2015.09.012"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","unstructured":"Thomas S Conway KM Fapo O et al. Time to diagnosis of Duchenne muscular dystrophy remains unchanged: findings from the muscular dystrophy surveillance tracking and research network 2000-2015. Muscle Nerve. 2022;66(2):193\u20137. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002%2Fmus.27532; DOI:10.1002\/mus.27532","DOI":"10.1002\/mus.27532"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012910"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"issue":"2007","key":"e_1_3_3_20_2","article-title":"Managing Duchenne muscular dystrophy\u2014the additive effect of spinal surgery and home nocturnal ventilation in improving survival","volume":"17","author":"Eagle M","year":"2007","unstructured":"Eagle M, Bourke J, Bullock R, et al. Managing Duchenne muscular dystrophy\u2014the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord. 2007;17(2007):470\u20135.","journal-title":"Neuromuscul Disord"},{"key":"e_1_3_3_21_2","unstructured":"Rohatgi A. WebPlotDigitizer. Available from: https:\/\/automeris.io\/. [Updated 2020; accessed 30 January 2025]."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","unstructured":"Picavet E Morel T Cassiman D Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9(1):62. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24767472; DOI:10.1186\/1750-1172-9-62","DOI":"10.1186\/1750-1172-9-62"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/currents.md.e1e8f2be7c949f9ffe81ec6fca1cce6a"},{"key":"e_1_3_3_24_2","unstructured":"The Cooperative International Neuromuscular Research Group. Duchenne natural history. Available from: https:\/\/cinrgresearch.org\/Duchenne-natural-history\/. [Accessed 8 July 2025]."},{"key":"e_1_3_3_25_2","unstructured":"Critical Path Institute. Duchenne regulatory science consortium (D-RSC). Available from: https:\/\/c-path.org\/program\/duchenne-regulatory-science-consortium\/. [Updated 2017; accessed 8 July 2025]."},{"key":"e_1_3_3_26_2","unstructured":"Broomfield J. Modelling the natural history of rare diseases using disparate data sources: application to patients with Duchenne muscular dystrophy. 2024. Available from: https:\/\/figshare.com\/articles\/thesis\/Modelling_the_Natural_History_of_Rare_Diseases_Using_Disparate_Data_Sources_pplication_to_Patients_with_Duchenne_Muscular_Dystrophy\/27073477"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","unstructured":"Ricotti V Ridout DA Pane M et al. The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2016;87(2):149\u201355. Available from: https:\/\/jnnp.bmj.com\/content\/87\/2\/149.full; DOI:10.1136\/jnnp-2014-309405","DOI":"10.1136\/jnnp-2014-309405"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","unstructured":"Brooke MH Griggs RC Mendell JR Fenichel GM Shumate JB Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186\u201397. Available from: https:\/\/api.istex.fr\/ark:\/67375\/WNG-42K8HSNJ-2\/fulltext.pdf; DOI:10.1002\/mus.880040304","DOI":"10.1002\/mus.880040304"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4247"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-023-00450-x"},{"key":"e_1_3_3_31_2","unstructured":"Duchenne UK. Project HERCULES: HEalth research collaboration united in leading evidence synthesis. Available from: https:\/\/www.duchenneuk.org\/project-hercules\/. [Updated 2022; accessed 1 February 2025]."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00613-8"},{"key":"e_1_3_3_33_2","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby K","year":"2010","unstructured":"Bushby K, Finkel F, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9:177\u201389.","journal-title":"Lancet Neurol"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30024-3"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","unstructured":"Zambon AA Ayyar Gupta V Ridout D et al. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev Med Child Neurol. 2022;64(8):979\u201388. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111%2Fdmcn.15176; DOI:10.1111\/dmcn.15176","DOI":"10.1111\/dmcn.15176"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011896"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/107327480701400209"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1201\/b13099"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.12.011"}],"container-title":["MDM Policy &amp; Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23814683261447231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23814683261447231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23814683261447231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T07:16:31Z","timestamp":1781334991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23814683261447231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/23814683261447231"],"URL":"https:\/\/doi.org\/10.1177\/23814683261447231","relation":{},"ISSN":["2381-4683","2381-4683"],"issn-type":[{"value":"2381-4683","type":"print"},{"value":"2381-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"23814683261447231"}}